{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-041066","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.466717+00:00","generated_at":"2026-05-22T04:57:19.940339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Longeveron Q1 net loss $5.0M; HLHS trial 95% enrolled, BLA on track for 2026","bullets":["Q1 2025 net loss $5.0M (up 23% YoY) on revenue $0.4M (down 30%); cash $14.3M, funding late into Q3 2025.","HLHS pivotal trial ELPIS II ~95% enrolled, completion Q2 2025; BLA submission for full traditional approval anticipated in 2026.","CLEAR MIND Alzheimer's Phase 2a results published in Nature Medicine; FDA agreed on pivotal Phase 2/3 trial design for BLA.","Company plans to seek additional financing and partnerships for BLA readiness and Alzheimer's program."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-041066","json":"https://secwatch.observer/filing/0001213900-25-041066.json","markdown":"https://secwatch.observer/filing/0001213900-25-041066.md","text":"https://secwatch.observer/filing/0001213900-25-041066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025041066/0001213900-25-041066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025041066/ea0241148-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:57:19.940339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}